Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We conditionally recommend annual screening for vitamin D deficiency over no screening or risk-stratified screening in individuals with Friedreich ataxia

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases

Study design awaiting verification · Orphanet Journal of Rare Diseases · 2022

Original publication title

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases

Louise A. Corben; Veronica Collins; Sarah Milne; Jennifer Farmer; Ann Musheno; David Lynch; Sub Subramony; Massimo Pandolfo; Jörg B. Schulz; Kim Lin; Martin B. Delatycki; the Clinical Management Guidelines Writing GroupAkhlaghiHamedBidichandaniSanjay I.BoeschSylviaCnopMiriamCortiManuelaDuquetteAntoineDurrAlexandraEigentlerAndreasEmmanuelAntonFlynnJohn M.ForoushNoushin ChiniFournierAnneFrançaMarcondes C.JrGiuntiPaolaGohEllen W.GrafLisaHadjivassiliouMariosHuckabeeMaggie-LeeKearneyMary G.KoeppenArnulf H.LieYenniLinKimberly Y.LowitAnjaMariottiCaterinaMathewsKatherineMcCormackShana E.MontenegroLisaMorletThierryNaeijeGillesPanickerJalesh N.ParkinsonMichael H.PatelAartiPayneRonald MarkPerlmanSusanPeverillRoger E.PoussetFrancoisePuccioHélèneRaiMyriamRanceGaryReetzKathrinRowlandTennille J.SansomPhoebeSavvatisKonstantinosSchallingEllika T.SchölsLudgerSmithBarbaraSoragniElisabettaSpencerCarolineSynofzikMatthisSzmulewiczDavid J.TaiGeneieveTamaroffJaclynTreatLaurenCarpentierAriane VeilleuxVogelAdam P.WaltherSusan E.WeberDavid R.WeisbrodNeal J.WilmotGeorgeWilsonRobert B.YoonGraceZesiewiczTheresa

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Evidence-based CMGs are required to ensure the best clinical care for people with FRDA. Adopting the GRADE rare-disease framework enabled the development of higher quality CMGs for FRDA and allows individual topics to be updated as new evidence emerges. While the primary goal of these guidelines is better outcomes for people living with FRDA, the process of developing the guidelines may also help inform the development of clinical guidelines in other rare diseases.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Individuals with Friedreich ataxia (FRDA) can find it difficult to access specialized clinical care. To facilitate best practice in delivering healthcare for FRDA, clinical management guidelines (CMGs) were developed in 2014. However, the lack of high-certainty evidence and the inadequacy of accepted metrics to measure health status continues to present challenges in FRDA and other rare diseases. To overcome these challenges, the Grading of Recommendations Assessment and Evaluation (GRADE) framework for rare diseases developed by the RARE-Bestpractices Working Group was adopted to update the clinical guidelines for FRDA.

This approach incorporates additional strategies to the GRADE framework to support the strength of recommendations, such as review of literature in similar conditions, the systematic collection of expert opinion and patient perceptions, and use of natural history data.

Source: Background

Abstract: What methods does the paper describe?

A panel representing international clinical experts, stakeholders and consumer groups provided oversight to guideline development within the GRADE framework. Invited expert authors generated the Patient, Intervention, Comparison, Outcome (PICO) questions to guide the literature search (2014 to June 2020). Evidence profiles in tandem with feedback from individuals living with FRDA, natural history registry data and expert clinical observations contributed to the final recommendations. Authors also developed best practice statements for clinical care points that were considered self-evident or were not amenable to the GRADE process.

Source: Methods

Abstract: Results

Seventy clinical experts contributed to fifteen topic-specific chapters with clinical recommendations and/or best practice statements. New topics since 2014 include emergency medicine, digital and assistive technologies and a stand-alone section on mental health. Evidence was evaluated according to GRADE criteria and 130 new recommendations and 95 best practice statements were generated.

Source: Results

Abstract: Discussion and conclusion

Evidence-based CMGs are required to ensure the best clinical care for people with FRDA. Adopting the GRADE rare-disease framework enabled the development of higher quality CMGs for FRDA and allows individual topics to be updated as new evidence emerges. While the primary goal of these guidelines is better outcomes for people living with FRDA, the process of developing the guidelines may also help inform the development of clinical guidelines in other rare diseases.

Source: Discussion and conclusion
Authors’ abstract

Background

Individuals with Friedreich ataxia (FRDA) can find it difficult to access specialized clinical care. To facilitate best practice in delivering healthcare for FRDA, clinical management guidelines (CMGs) were developed in 2014. However, the lack of high-certainty evidence and the inadequacy of accepted metrics to measure health status continues to present challenges in FRDA and other rare diseases. To overcome these challenges, the Grading of Recommendations Assessment and Evaluation (GRADE) framework for rare diseases developed by the RARE-Bestpractices Working Group was adopted to update the clinical guidelines for FRDA.

This approach incorporates additional strategies to the GRADE framework to support the strength of recommendations, such as review of literature in similar conditions, the systematic collection of expert opinion and patient perceptions, and use of natural history data.

Methods

A panel representing international clinical experts, stakeholders and consumer groups provided oversight to guideline development within the GRADE framework. Invited expert authors generated the Patient, Intervention, Comparison, Outcome (PICO) questions to guide the literature search (2014 to June 2020). Evidence profiles in tandem with feedback from individuals living with FRDA, natural history registry data and expert clinical observations contributed to the final recommendations. Authors also developed best practice statements for clinical care points that were considered self-evident or were not amenable to the GRADE process.

Results

Seventy clinical experts contributed to fifteen topic-specific chapters with clinical recommendations and/or best practice statements. New topics since 2014 include emergency medicine, digital and assistive technologies and a stand-alone section on mental health. Evidence was evaluated according to GRADE criteria and 130 new recommendations and 95 best practice statements were generated.

Discussion and conclusion

Evidence-based CMGs are required to ensure the best clinical care for people with FRDA. Adopting the GRADE rare-disease framework enabled the development of higher quality CMGs for FRDA and allows individual topics to be updated as new evidence emerges. While the primary goal of these guidelines is better outcomes for people living with FRDA, the process of developing the guidelines may also help inform the development of clinical guidelines in other rare diseases.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13023-022-02568-3.

Publication and source details

Original title: Clinical management guidelines for Friedreich ataxia: best practice in rare diseases

Louise A. Corben; Veronica Collins; Sarah Milne; Jennifer Farmer; Ann Musheno; David Lynch; Sub Subramony; Massimo Pandolfo; Jörg B. Schulz; Kim Lin; Martin B. Delatycki; the Clinical Management Guidelines Writing GroupAkhlaghiHamedBidichandaniSanjay I.BoeschSylviaCnopMiriamCortiManuelaDuquetteAntoineDurrAlexandraEigentlerAndreasEmmanuelAntonFlynnJohn M.ForoushNoushin ChiniFournierAnneFrançaMarcondes C.JrGiuntiPaolaGohEllen W.GrafLisaHadjivassiliouMariosHuckabeeMaggie-LeeKearneyMary G.KoeppenArnulf H.LieYenniLinKimberly Y.LowitAnjaMariottiCaterinaMathewsKatherineMcCormackShana E.MontenegroLisaMorletThierryNaeijeGillesPanickerJalesh N.ParkinsonMichael H.PatelAartiPayneRonald MarkPerlmanSusanPeverillRoger E.PoussetFrancoisePuccioHélèneRaiMyriamRanceGaryReetzKathrinRowlandTennille J.SansomPhoebeSavvatisKonstantinosSchallingEllika T.SchölsLudgerSmithBarbaraSoragniElisabettaSpencerCarolineSynofzikMatthisSzmulewiczDavid J.TaiGeneieveTamaroffJaclynTreatLaurenCarpentierAriane VeilleuxVogelAdam P.WaltherSusan E.WeberDavid R.WeisbrodNeal J.WilmotGeorgeWilsonRobert B.YoonGraceZesiewiczTheresa

Orphanet Journal of Rare Diseases · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/100002108Friedreich's Ataxia Research Alliance

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:49:03.391526+00:00

DOI: 10.1186/s13023-022-02568-3 · PMC9652828